Clinical safety and efficacy of tianeptine in 1,858 depressed patients treated in general practice
Guelfi JD, Dulcire C, Le Moine P, Tafani A.
CMME, Service du Pr. Samuel-Lajeunesse, Paris, France.
Neuropsychobiology. 1992;25(3):140-8.


1,927 outpatients were included by 392 general practitioners in an open study in order to evaluate the safety of tianeptine in the ambulatory treatment of depression. The results of 1,858 depressed patients without melancholia and psychotic features, fulfilling DSM III criteria of Major Depressive Episode or Dysthymic Disorder, could be analysed. 1,458 patients completed the 3-month treatment period. The group treated with 37.5 mg/day of tianeptine showed improvement on the Montgomery-Asberg Depression Rating Scale. With regard to the clinical tolerance of tianeptine, somatic complaints were rarely reported and adverse events necessitating premature termination of treatment (4.8% of included patients) were without clinical severity. Cardiovascular, haematologic, hepatic and biochemical safety were verified. No signs of dependence and no specific withdrawal symptoms were found after discontinuation of treatment.
Asthma prevention
Anxious depression
Tianeptine (Stablon)
Tianeptine: structure
Apoptosis prevention
Dopamine and neuroplasticity
Tianeptine and Panic Disorder
Ethanol withdrawal and tianeptine
Discriminative stimulus properties
Neurobiology of mood, anxiety and emotion
Major depression treated with tianeptine (Stablon)

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family